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ABSTRACT
Background: We examined the psychometric properties of the Korean version of the 8-item Morisky Medication
Adherence Scale (MMAS-8) among adults with hypertension.
Methods: A total of 373 adults with hypertension were given face-to-face interviews in 2 cardiology clinics at 2
large teaching hospitals in Seoul, South Korea. Blood pressure was measured twice, and medical records were
reviewed. About one-third of the participants (n = 109) were randomly selected for a 2-week test-retest evaluation of
reliability via telephone interview.
Results: Internal consistency reliability was moderate (Cronbach α = 0.56), and test-retest reliability was excellent
(intraclass correlation = 0.91; P < 0.001), although a ceiling effect was detected. The correlation of MMAS-8 scores
with scores for the original 4-item scale indicated that convergent validity was good (r = 0.92; P < 0.01). A low
MMAS-8 score was significantly associated with poor blood pressure control (χ2 = 29.86; P < 0.001; adjusted odds
ratio = 5.08; 95% CI, 2.56–10.08). Using a cut-off point of 6, sensitivity and specificity were 64.3% and 72.9%,
respectively. Exploratory factor analysis identified 3 dimensions of the scale, with poor fit for the 1-dimensional
construct using confirmatory factory analysis.
Conclusions: The MMAS-8 had satisfactory reliability and validity and thus might be suitable for assessment and
counseling regarding medication adherence among adults with hypertension in a busy clinical setting in Korea.
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INTRODUCTION
Inadequate adherence to antihypertensive drug therapy is a
very common factor in uncontrolled blood pressure (BP).1,2
The World Health Organization (2003) estimated that
adherence rates range from 50% to 70%, although the
relevant studies varied with respect to study population,
duration of follow up, and method used to assess adherence.3
In Korea, the rate of adherence to antihypertensive
medications, as measured by self-report of regular
medication use, was 61.1%.4 In the context of doctor-patient
interaction in ordinary Korean clinical settings, this finding
can be explained by 2 types of factors. First, many
individuals with hypertension have negative feelings toward
antihypertensive drugs and lack knowledge of hypertension.
For example, they sometimes do not appreciate the need
to continue medication even when they no longer have
symptoms.5 Second, although physicians should carefully
assess noncompliance with antihypertensive drugs and
inform patients about hypertension management, they are
unable to do so due to the limited time for physician
consultation and lack of attention to BP control.6 These
limitations might be due to characteristics of the Korean
health care system, such as the fact that reimbursement for
outpatients is based on a fee-for-service model rather than on
capitation payment.
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In this context, the simplicity of the 8-item Morisky
Medication Adherence Scale (MMAS-8) as a self-reported
measure could make it a very practical approach to assess
adherence to an antihypertensive treatment regimen.7,8
Moreover, this questionnaire could help to stimulate
physician-patient dialogue on antihypertensive medication
because the scale items illustrate adherence behaviors that
occur most frequently in practice.8 Although a self-report
measure might be limited by recall bias and overestimation,9
the simplicity of such an instrument could reduce barriers to
medication adherence and increase feasibility in busy clinics,
thus offsetting those disadvantages.
We assessed the psychometric properties of the Korean
version of the MMAS-8. The English version of the MMAS-8
has shown good validity and reliability among a population
made up primarily of low-income black and Hispanic adults
with hypertension in the United States.10 The reliability and
validity of the MMAS-8 has also been examined among
patients with diabetes in Thailand and Malaysia,11,12 among
patients with hypertension in France,13 and among patients
taking warfarin in Singapore.14
METHODS
Participants
This study was performed between May and September in
2010 in cardiology clinics at the Chung-Ang University Yong
San Hospital and Chung-Ang University Hospital in Seoul,
which are large teaching hospitals in the same university
educational foundation. To provide good precision for factor
analysis, the estimated target sample size was 160 patients,
using a ratio (sample size: number of items) of 20:1.15 To
overcome the skewed distribution of high MMAS-8 scores in
the sample and increase outcome validity the size of the target
sample was increased by a factor of 2.5, resulting in a final
sample size of 400 patients. During the study period 400
consecutive patients with hypertension who met the eligibility
criteria for this study were selected at the clinics (Figure 1).
The eligibility criteria were age older than 30 years, ability to
communicate in the Korean language, receipt of a prescription
for antihypertensive medication at the clinics during the 30
days before the study began, and no signs or symptoms of
severe health problems such as cancer or chronic heart failure.
During this period, 373 (93.3%) of the 400 patients with
hypertension agreed to participate (Figure 1). The reasons for
nonparticipation among the other 27 patients were insufficient
time for participation (n = 22) and unwillingness to divulge
personal information (n = 5). This study was approved by
the Ethics Committee of Chung-Ang University Yong San
Hospital and Chung-Ang University Hospital.
Instrument and translation
The MMAS-8 was developed from a previously validated 4-
item scale and supplemented with additional items regarding
the context of adherence behavior.15 The theory underlying
this measure is that failure to adhere to a medication regimen
could be due to several factors, as expressed in the questions,
“Do you sometimes forget to take your medication?”, “Do you
stop taking medications when feeling worse?”, and “Do you
feel hassled about sticking to a treatment plan?”. Each item
measures a specific medication-taking behavior and not a
determinant of adherence. Response categories are yes/no
(dichotomous response) for items 1 through 7; item 8 uses a
5-point Likert scale. MMAS-8 scores range from 0 to 8 and
have been trichotomized into 3 adherence levels to facilitate
use in clinical practice, namely, high adherence (a score of 8),
medium adherence (a score of ≥6 to <8), and low adherence
(a score of <6). There are several reasons for dividing the
score into 3 rather than 2 categories. First, numerous
investigators have identified a linear positive correlation
between MMAS-8 scale score and physiological response.
Second, by dividing the scale into 3 categories, resources can
be directed to patients having the greatest difficulty adhering
to a treatment regimen, eg, by providing tailored educational
counseling to address misconceptions regarding adherence.
Finally, patients with high scores on the MMAS-8 can serve
as models in focus group sessions, by detailing the processes
by which they internalize adherence into their daily lifestyle.
For this study, hypertension was inserted into each item
of the 8-item MMAS, which was then translated into Korean
using forward and backward translation, using the
recommendations of Wild et al for the translation and
adaptation of patient-centered outcome measures.16 First, the
original MMAS was forward-translated into the Korean by 2
qualified, independent language translators, both of whom
were native speakers of Korean and proficient in English.
Researchers reviewed the 2 primary versions and reached
a consensus on a draft Korean version. Second, a bilingual
Korean-Canadian expert translated the Korean draft back
into English. Translators and researchers then compared the
conceptual equivalence of the back-translated English version
and the original. Third, the translated questionnaire was
distributed to 30 Korean adults with hypertension who then
completed the questionnaire and commented on the questions.
These individuals were not included in the present study.
Their comments were discussed by the researchers, after
which a Korean final version was completed and made
available for assessment of reliability and validity.
Measurements
Face-to-face interviews were conducted to administer the
MMAS-8 and collect data on sociodemographic
characteristics and health behaviors such as smoking and
alcohol consumption. At the same time, a calibrated mercury
sphygmomanometer was used to measure BP twice, with a
minimum interval of 5 minutes between measurements. All
measurements were taken by a trained nurse according to
guidelines established in the Seventh Report of the Joint
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National Committee.17 The patients’ medical records were
reviewed to collect clinical information such as duration
of hypertension, number of prescribed antihypertensive
medications, and comorbidities. In addition, about one-third
of the sample (n = 109) was randomly selected (using SPSS
statistical software) to evaluate 2-week test-retest reliability
via telephone. All patients who agreed to participate in
telephone interviews were interviewed by the same people
who conducted their baseline interviews.
Statistical analysis
Sociodemographic characteristics, health behaviors, clinical
characteristics, and MMAS-8 scores of the patients were
assessed in relation to MMAS-8 category (high, moderate,
low). The statistical significance of the characteristics and
scores across the 3 adherence categories was determined using
analysis of a variance (ANOVA) and χ2 tests for continuous
variables and categorical variables, respectively. Potential
ceiling and floor effects, which can affect reliability and
validity, were considered if more than 15% of respondents
achieved the lowest or highest possible total scores.18
Internal consistency of the 8-item scale was assessed using
Cronbach α. Intraclass correlation (ICC) was used to assess
test-retest reliability. According to Nunnally and Bernstein,
newly developed measures can be accepted with a Cronbach α
greater than 0.5; 0.7 should be the threshold in other cases.19
We considered an ICC less than 0.4 as poor, an ICC of 0.4
to 0.75 as fair or good, and an ICC greater than 0.75 as
excellent.20
Convergent validity was evaluated using Pearson
correlation coefficients between the MMAS-8 and the
previous 4-item Morisky, Green, and Levine scale.21 Three
items from the MMAS-8 are identical to items on the previous
4-item scale and were thus used to represent the previous
scale. Known-groups validity was assessed using the
association of MMAS-8 categories (high, moderate, low
adherence) with BP control, as determined by the χ2 test.
Additionally, multiple logistic regression was used to calculate
odds ratios (ORs) for the association between MMAS-8
category and BP control, adjusted for age, sex, education,
smoking, alcohol, obesity, duration of hypertension, number
of antihypertensive drugs, and comorbidities.
MMAS-8
Translation (2 independent linguistic translators) and back-
translation (bilingual translator)
Translation committee
English linguist
Medical doctor
Psychologist
Epidemiologist
Pilot survey of 30 hypertension patients conducted with draft 
Korean version of MMAS
Korean version of MMAS-8
IRB approval
Patients with hypertension who presented at clinics at Chung-
Ang Yongsan Hospital and Chung-Ang Hospital between May  
and SeptemberEligibility criteria
Korean language proficiency
Age 30 years
Receipt of 1 prescription at 
hospital
No evidence of severe health
conditions (cancer, heart failure)
Reasons for non-participation  (27)
Insufficient time (22)
Unwilling to divulge personal 
information (5)
400 consecutive patients 
selected at clinics  
373 patients agreed to 
participate 
109 patients randomly selected 
for test-retest analysis
Figure 1. Study design. MMAS-8 = 8-item Morisky Medication Adherence Scale, IRB = institutional review board.
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Confirmatory factor analysis (CFA) and exploratory factor
analysis (EFA)22 were used to examine the structural validity
of the Korean version of the MMAS-8. First, CFA was
used to evaluate fit of the scale in a 1-factor model, as in
previous studies.10,12–14 The indices used to assess fit of
the model were root mean square error of approximation
(RMSEA), the Tucker-Lewis index (TLI) (also known as
the non-normed fit index [NNFI]), and the comparative fit
index (CFI). The goodness-of-fit criteria for each index were
a TLI (NNFI) and CFI greater than 0.9 and an RMSEA less
than 0.05.23–25 Second, EFA was used to identify factors
unique to Korean patients with hypertension in the sample
data. EFA with varimax rotation was used, and only factors
with an eigenvalue greater than 1 were considered to
contribute significantly to explaining variance. A factor
loading greater than 0.3 on an item was considered to
belong to the corresponding factor.26 All analyses were
performed using IBM SPSS version 20.0 software with
AMOS version 20.0. The level of significance was set at P
less than 0.05.
RESULTS
A total of 373 participants completed the study (Table 1).
There were no significant differences among the 3 adherence
groups with respect to sex, education level, number of
comorbidities, or body mass index (BMI). However, there
were significant differences in age, smoking status, frequency
of alcohol drinking, duration of hypertension, systolic BP,
diastolic BP, number of antihypertensive drugs, and MMAS-8
score. The distribution of MMAS scores was skewed
(Figure 2), and the median was 7.0 (range, 2.5–8.0). A
ceiling effect was observed, as almost one-third (34.0%)
of respondents had a score of 8, ie, highest adherence to
the hypertension treatment regimen. The distributions of
responses to each item on the 8-item MMAS are shown in
Table 2. The items with response rates greater than 50%,
indicating good adherence, were not forgetting to take
diabetes medications (63.8%) and having no days on which
medication was not taken during the previous 2 weeks
(64.9%). In contrast, more than 90% of respondents reported
that they had taken their hypertension medications on the
previous day and that they had not decided to stop or reduce
their hypertension medications when they felt worse or better.
In addition, most respondents never (59.0%) or rarely (35.4%)
had difficulty remembering their medications.
The Cronbach α for internal consistency was 0.56 for the
MMAS-8 scale, which is below the generally accepted value
of 0.70. However, the test-retest reliability of the MMAS-8
was excellent (ICC, 0.91; P < 0.001).
Analysis of convergent validity showed that the MMAS-8
was positively associated with the original 4-item Morisky,
Green and Levine scale (r = 0.92; P < 0.01). The MMAS-8
had a good correlation with the 4-item Morisky scale.
Data on known-groups validity are shown in Tables 3
and 4. As shown in Table 3, the χ2 test showed a significant
relationship between MMAS-8 adherence category and BP
control (χ2 = 29.86, P < 0.001). As shown in Table 4, the
prevalence of poor BP control (systolic BP ≥140mmHg or
diastolic BP ≥90mmHg) in the low adherence group
(MMAS-8 score <6) was about 5.1 times that among those
with an MMAS-8 score of 6 or higher (adjusted OR, 5.08;
95% CI, 2.56–10.08).
The MMAS-8 showed low-to-moderate criterion-related
validity, as shown in Table 3. With a cut-off point of 6 (low
adherence, MMAS-8 score <6), the sensitivity, specificity,
positive predictive value, and negative predictive value of
the MMAS-8 were 64.3%, 72.9%, 29.5%, and 92.0%
respectively. This sensitivity means that 64.3% of
hypertensive patients who had poor BP control had low
adherence (MMAS-8 score, <6), while the specificity
indicates that 72.9% of patients with good BP control had
moderate (MMAS-8 score, 6 to <8) or high (MMAS-8 score,
8) adherence to their medication. The positive predictive value
indicates that 29.5% of the participants with low adherence
had poorly controlled BP, whereas the negative predictive
value means that 92.0% of those with moderate-to-high
adherence had good BP control. When we changed the cut-off
score for low adherence from 6 to 7 (low adherence, MMAS-8
score of <7), sensitivity, specificity, positive predictive value,
and negative predictive value were 75.0%, 58.4%, 24.1%, and
93.0% respectively. Similarly, if the cut-off score was raised
to 8 (low adherence, MMAS-8 score of <8), sensitivity,
specificity, positive predictive value, and negative predictive
value were 82.1%, 36.9%, 18.7%, and 92.1%, respectively.
CFA for the 1-factor model of the MMAS-8 showed a poor
fit on the fit indices (RMSEA = 0.087, TLI = 0.825, and
CFI = 0.875). As shown in Table 5, EFA showed 3 factors
with eigenvalues greater than 1, which explained 58.5% of the
total variance. Factor loadings between the 8 items of the
MMAS and the 3 factors are presented. Factor 1 comprised
items 1, 2, 4, 5, and 8, which mostly concern forgetting to take
medications. Factor 2 consisted of items 3 and 6, which
concern stopping medications when feeling better or worse.
Factor 3 included only item 7, which concerns the view that
taking medications daily is difficult.
DISCUSSION
It is important to note that a ceiling effect was observed for the
8-item MMAS both in this study and in 2 previous studies.11,14
The consequences of a significant ceiling effect are that (1)
changes in health behaviors cannot be measured in patients
with the highest possible score and (2) false-negative case-
findings (patients with the highest score on the scale and no
BP control) are likely to be due to the limited number of items
used to assess compliance behaviors.18,27 When observing
changes in compliance with an antihypertensive medication
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regime, if response choices are added to the 7 items with
binary responses (yes/no), score variability could improve
among patients with the highest possible scores. Although
specificity would be lower, this is considered an acceptable
trade-off because sensitivity is more important than specificity
in a clinical setting.
The Cronbach α for the MMAS-8 was below the acceptable
level of 0.7 in previous studies11–14 (range, 0.54–0.67) and the
present study (0.56). However, the low α in this study might
be an underestimate of the internal consistency reliability of
the scale, as 2 of the conditions required for Cronbach α to be
an accurate estimate of reliability were not met.28–31 First, if α
is to be a good estimate of reliability, then the measures
involved should be unidimensional. Our EFA showed that the
scale had 3 dimensions, ie, that there were 3 different traits in
this scale. This could explain why α was lower than the
acceptable level of 0.7. Moreover, if the number of test items
is too small, α will underestimate the reliability of the scale.
Another explanation for the moderate Cronbach α is the low
variability in the scale scores, which indicates that about half
of the subjects in this study had values of 7 or 8, as shown
in Figure 2. Internal consistency would be improved if
variability among scale scores were greater, which would
occur in a population with different levels of adherence.32 For
Table 1. Characteristics of participants, by adherence category
Characteristic
Total Sample
(n = 373)
High Adherence
(MMAS = 8, n = 127)
Moderate Adherence
(6 ≤ MMAS < 8, n = 124)
Low Adherence
(MMAS < 6, n = 122)
Age, yearsb
Mean (SD) 57.2 (11.20) 60.7 (10.49) 57.41 (11.2) 53.4 (10.8)
Range 30–83 30–82 32–83 30–82
Sex, %a
Female 45.0 46.5 48.4 40.2
Male 55.0 53.5 51.6 59.8
Education, %a
≤6th grade 13.4 12.5 16.9 10.7
7th–12th grade 45.8 52.8 41.9 42.6
College (2–4 years) 32.2 26.8 33.1 36.9
Graduate school 8.6 7.9 8.1 9.8
Body mass indexa
Mean (SD) 25.0 (3.2) 25.1 (3.1) 24.7 (3.1) 25.4 (3.1)
Range 17.9–39.6 17.9–39.6 18.3–38.2 18.4–34.4
Smoking statusb
Nonsmoker 59.4 63.8 66.1 47.9
Ex-smoker 23.9 22.0 19.4 30.6
Current smoker 16.7 14.2 14.5 21.5
Frequency of alcohol drinkingb
None 47.7 58.3 48.4 36.1
1/month 11.0 8.7 9.7 14.8
2–3/month 5.1 3.1 4.0 8.2
2–3/week 29.8 22.0 32.3 35.2
≥4/week 6.4 7.9 5.6 5.7
Duration of hypertension, monthsb
Mean (SD) 52.75 (52.0) 62.2 (51.9) 54.8 (56.8) 40.9 (44.5)
Range 1.6–286.7 1.7–286.7 1.6–268.4 2.8–270.7
Systolic blood pressure, mmHgb
Mean (SD) 126.29 (10.4) 125.22 (8.3) 124.2 (8.9) 129.6 (12.9)
Range 99.0–189.0 110.0–150.0 102.5–150.0 99.0–189.0
Diastolic blood pressure, mmHgb
Mean (SD) 82.5 (6.7) 81.3 (4.9) 81.7 (6.2) 84.7 (8.1)
Range 67.5–120.5 68.8–98.0 68.5–99.5 67.5–120.5
No. of comorbidities, %a
0 81.2 80.3 83.1 80.3
1 17.4 18.1 14.5 19.7
≥2 1.3 1.6 2.4 —
Antihypertensive drugs, nb
Mean (SD) 2.2 (0.98) 2.4 (0.98) 2.2 (1.00) 2.02 (0.90)
Range 1–5 1–5 1–5 1–4
MMASb,c
Mean (SD) 6.6 (1.4) 8.0 (0.0) 6.8 (0.4) 5.0 (0.9)
Range 2.5–8.0 8.0–8.0 6.0–7.8 2.5–5.8
MMAS-8, 8-item Morisky Medication Adherence Scale.
aNo significance difference among adherence groups (P ≥ 0.05).
bSignificant difference among adherence groups (P < 0.05).
cHigher MMAS scores indicate greater adherence to medication.
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instance, when the analysis was limited to patients with
hypertension for less than 1 year (n = 74), Cronbach α
increased to 0.60 because the variability in scale scores was
greater among these patients. The proportion of those with a
scale score greater than 7 was about 30%.
Finally, because 7 of the 8 items on the scale require binary
responses (yes/no), which tends to decrease Cronbach α,
internal consistency reliability could be improved by
increasing the number of response choices.32 However, this
was attempted on the Morisky, Green and Levine scale,21 with
no change in internal consistency Nevertheless, the MMAS-8
had excellent test-retest reliability (ICC = 0.91, P < 0.001),
indicating good stability of the scale over time. Excellent test-
retest reliability has also been observed in other studies.11–13
Convergent validity was supported by the significant
correlation with the previous 4-item scale (r = 0.92;
P < 0.01), which was also shown in other studies.11,12 For
known-groups validity, we found a significant association
Table 2. Distribution of responses to items on 8-item MMAS
Items 1–7
No
n (%)
Yes
n (%)
1. Do you sometimes forget to take your hypertension medications? 238 (63.8) 135 (36.2)
2. People sometimes miss taking their medications for reasons other than forgetting. Thinking over the past
two weeks, were there any days when you did not take your hypertension medicine?
242 (64.9) 131 (35.1)
3. Have you ever cut back or stopped taking your medication without telling your doctor because you felt
worse when you took it?
360 (96.5) 13 (3.5)
4. When you travel or leave home, do you sometimes forget to bring along your hypertension medications? 305 (81.8) 68 (18.2)
5. Did you take your hypertension medicine yesterday? 29 (7.8) 344 (92.2)
6. When you feel like your blood pressure is under control, do you sometimes stop taking your medicine? 346 (92.8) 27 (7.2)
7. Taking medication every day is a real inconvenience for some people. Do you ever feel hassled about
sticking to your hypertension treatment regimen?
302 (81.0) 71 (19.0)
Item 8
Never
n (%)
Rarely
n (%)
Sometimes
n (%)
Often
n (%)
Always
n (%)
8. How often do you have difficulty remembering to take all your
hypertension medications?
220
(59.0)
132
(35.4)
19
(5.1)
2
(0.5)
0
(0.0)
MMAS, Morisky Medication Adherence Scale.
Use of the MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD,
ScM, MSPH, Professor, Department of Community Health Sciences, UCLA Fielding School of Public Health, 650 Charles E. Young Drive South,
Los Angeles, CA 90095-1772.
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Figure 2. Distribution of scores on 8-item Morisky Medication Adherence Scale.
Table 3. Relationship between MMAS-8 and blood pressure
control
Parameter
Blood pressure controla
Total
n (%)Poor control
n (%)
Good control
n (%)
Low adherence (MMAS < 6) 36 (29.5) 86 (70.5) 122 (100)
Moderate adherence (6 ≤ MMAS < 8) 10 (8.1) 114 (91.9) 124 (100)
High adherence (MMAS = 8) 10 (7.9) 117 (92.1) 127 (100)
Total 56 (15.0) 317 (85.0) 373 (100)
MMAS-8, 8-item Morisky medication adherence scale.
aNo. (%) of patients: χ2 = 29.855; P < 0.001.
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(χ2 = 29.86; P < 0.001) between MMAS-8 adherence category
and BP control, as was noted in other studies.11,12 The
adjusted OR for low adherence to poor BP control, which
considered confounding variables for those associations, was
5.08 (95% CI, 2.56–10.08). These findings indicate that the
scale could differentiate between patients with well and poorly
controlled BP (systolic BP <140mmHg or diastolic BP
<90mmHg).
However, using BP control as the gold standard, criterion-
related validity was low or moderate, as was the case in
previous studies.11,12 A possible reason for this finding is
overestimation of adherence levels due to recall bias and
social desirability. Adherence to medication can increase the
number of clinic appointments, which might have a large
effect on patient recall when the questionnaire was
administered during a clinic appointment for hypertension
treatment.33 Social desirability might have had an effect on
question responses in the present study.34 Intentional
nonadherence (eg, ceasing hypertension medication when
feeling worse) was much less frequent than unintentional
Table 4. Odds ratios for poor blood pressure control associated with sociodemographic factors and adherence in univariate
logistic regression and 2 multivariate logistic regression models
Univariate analysis Model Ic Model IId
ORa 95% CIb ORa 95% CIb OR 95% CIa,b
Age 0.962 0.937–0.987 0.975 0.938–1.013 0.981 0.943–1.021
Sex
Male Reference Reference Reference
Female 0.528 0.290–0.960 0.617 0.228–1.668 0.636 0.237–1.712
Education
≤6th grade 0.456 0.117–1.777 0.884 0.173–4.518 0.872 0.170–4.468
7th–12th grade 0.812 0.305–2.161 0.924 0.286–2.983 0.855 0.257–2.841
College (2–4 years) 0.815 0.296–2.247 0.710 0.224–2.252 0.687 0.213–2.217
Graduate school Reference Reference Reference
BMI
Underweight 1.500 0.117–19.178 2.064 0.048–89.656 2.618 0.048–144.023
Normal 0.413 0.160–1.066 0.515 0.174–1.520 0.635 0.201–2.003
Overweight 0.629 0.238–1.660 0.608 0.207–1.791 0.738 0.238–2.288
Obese Reference Reference Reference
Smoking status
Current smoker 2.727 1.348–5.518 1.396 0.524–3.722 1.489 0.552–4.013
Ex-smoker 1.463 0.722–2.966 0.611 0.215–1.738 0.654 0.227–1.886
Nonsmoker Reference Reference Reference
Frequency of alcohol drinking
None
1/month Reference Reference Reference
2–3/month 0.346 0.078–1.529 0.211 0.045–0.998 0.219 0.046–1.037
2–3/week 1.797 0.549–5.888 0.674 0.160–2.851 0.661 0.156–2.808
≥4/week 1.572 0.824–3.000 0.703 0.274–1.799 0.697 0.269–1.803
2.246 0.808–6.245 1.256 0.336–4.691 1.167 0.302–4.515
Duration of hypertension (months) 0.995 0.988–1.001 0.995 0.987–1.004
No. of comorbidities
0 Reference Reference
1 0.764 0.343–1.706 0.849 0.342–2.106
≥2 1.362 0.149–12.454 3.165 0.307–32.632
No. of antihypertensive drugs 1.157 0.868–1.542 1.304 0.919–1.850
Adherence group
Low 4.835 2.653–8.810 4.890 2.529–9.456 5.075 2.555–10.079
Moderate/high Reference Reference Reference
aOdds ratio.
bConfidence interval.
cAdjusted for age, sex, education, body mass index (BMI), smoking status, frequency of alcohol drinking.
dAdjusted for covariates in Model I plus duration of hypertension, number of comorbidities, and number of antihypertensive drugs.
Poor blood pressure control: systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg.
Table 5. Exploratory factor analysis of the 8-Item Morisky
Medication Adherence Scale in patients with
hypertensiona
Item Factor 1 Factor 2 Factor 3
1 0.799 0.090 −0.143
2 0.628 0.111 0.159
3 0.032 0.780 0.037
4 0.531 −0.317 0.027
5 0.413 0.224 0.049
6 0.162 0.783 0.002
7 0.067 0.030 0.982
8 0.862 0.094 0.061
aFactor loading in 373 patients.
Bold-faced numbers indicate a factor loading >0.3.
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nonadherence (ie, forgetting to take hypertension medication),
which suggests that patients could have answered questions in
a way that increased MMAS scores even though their BP
control was less than satisfactory. Increasing the cut-off score
for low adherence from 6 to 8 would improve sensitivity,
but at the expense of specificity. Nevertheless, this may be
preferable because, in clinical practice, health care providers
are more interested in identifying patients with both poor BP
control and low adherence than in discovering those with
good control and high adherence.
CFA of the unidimensional structure of the MMAS-8 in
previous studies10,12–14 showed a poor fit in the present study.
Construct validity analyzed by EFA with varimax rotation
showed that the MMAS-8 had 3 factors with eigenvalues
greater than 1: factor 1 (items 1, 2, 4, 5, and 8), factor 2 (items
3 and 6), and factor 3 (item 7). These results are similar to
those reported in a study using a Thai version of the scale for
patients with Type 2 diabetes.11 According to Morisky and
colleagues,10 the MMAS-8 theoretically measures a specific
medication-taking behavior that leads to failed adherence and
not a determinant of adherence behavior. They indicated that
this measurement could theoretically have more than 1 factor.
Thus, it is unsurprising that the MMAS-8 showed 3 factors
in this study and the study using the Thai version of the
MMAS-8.11
This study had limitations. The respondents were recruited
from outpatient clinics at 2 tertiary hospitals; therefore, the
study sample was vulnerable to selection bias. Individuals
with hypertension who are treated in outpatient clinics
at tertiary hospitals must pay substantial out-of-pocket
payments. Therefore, they are much more likely to adhere
to their prescribed treatment, as compared with people with
hypertension living in the community. In addition, MMAS
scores may have been affected by social desirability and recall
bias.
It may be necessary to modify the Korean MMAS-8 by
increasing the number of response choices when examining
changes in adherence after an intervention such as education.35
Nevertheless, the acceptable test-retest reliability and good
convergent, known-groups, and construct validity indicate that
the 8-item MMAS can be useful in assessing medication
adherence among people with hypertension in a busy clinic
in Korea. Moreover, it could help in identifying barriers to
adherence and in developing targeted interventions to improve
adherence by means of a “teachable moment” in a busy
clinical setting. For example, when a physician identifies
a patient with poor BP control who voluntarily stopped
antihypertensive medication, the physician can immediately
counsel the patient regarding the medication. Alternatively,
for patients with an MMAS score of 8 and poor BP control,
a change in therapy might be needed to achieve appropriate
BP control. Our results may not be generalizable to other
diseases. Thus, further research is needed in order to analyze
the psychometric properties of the MMAS-8 in Koreans
with other chronic conditions requiring long-term medical
treatment, such as osteoporosis, ulcerative colitis, and
tuberculosis.
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